Forty Seven

YTD

ALL

Why Robinhood?

You can watch Forty Seven and buy or sell other stocks, ETFs, and their options commission-free!

About FTSV

Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a ''don't eat me'' signal that cancer cells commandeer to avoid being ingested by macrophages.

CEO

Mark A. McCamish, MD, PhD

CEOMark A. McCamish, MD, PhD

Employees

—

Employees—

Headquarters

Menlo Park, California

HeadquartersMenlo Park, California

Founded

2014

Founded2014

Employees

—

Employees—

FTSV Key Statistics

Market cap

4.60B

Market cap4.60B

Price-Earnings ratio

-38.73

Price-Earnings ratio-38.73

Dividend yield

—

Dividend yield—

Average volume

1.26M

Average volume1.26M

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$95.52

52 Week high$95.52

52 Week low

$5.53

52 Week low$5.53